Moderna’s flu vaccine elicited a better immune response than existing jabs in a late-stage trial, paving the way for the Boston-based biotech company to enter the $6bn annual market.
The company — whose first approved vaccine was for Covid-19 — reported initial data on antibody levels that suggested its vaccine could compete against GSK’s Fluarix. It is discussing the approval process with regulators.
In another trial, the vaccine elicited a higher antibody response than French drugmaker Sanofi’s Fluzone high-dose, which is often used to vaccinate older people.
您已閱讀18%（566字），剩余82%（2542字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。